Close

Curaleaf (CURLF) PT Raised to $26.50 at Cantor Fitzgerald Following Q4 Results

Go back to Curaleaf (CURLF) PT Raised to $26.50 at Cantor Fitzgerald Following Q4 Results

Curaleaf Reports Record Fourth Quarter and Fiscal Year End 2020 Financial and Operational Results

March 9, 2021 4:04 PM EST

WAKEFIELD, Mass., March 9, 2021 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, today reported its financial and operating results for the fourth quarter and year ended December 31, 2020. All financial information is provided in U.S. dollars unless otherwise indicated.

Q4 and FY2020 Financial Highlights (Unaudited)

($ thousands, except per share amounts)

Q4 2020

Q3... More

Curaleaf to Enter European Cannabis Market with Acquisition of EMMAC Life Sciences Limited - Europe's Leading Independent Cannabis Company

March 9, 2021 4:01 PM EST

WAKEFIELD, Mass., March 9, 2021 /PRNewswire/ -- Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, today announced that it has signed a definitive agreement to acquire EMMAC Life Sciences Limited ("EMMAC"), the largest vertically integrated independent cannabis company in Europe for base consideration of approximately US$286 million to be paid 85% in Curaleaf subordinate voting shares and 15% in cash. Contingent consideration of up to US$57 million will be paid in Curaleaf subordinate voting... More